2018
The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM)
Kenyon E, Lipscomb J, Pegram R, George B, Hines R. The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM). Toxicological Sciences 2018, 167: 347-359. PMID: 30252107, PMCID: PMC10448349, DOI: 10.1093/toxsci/kfy236.Peer-Reviewed Original ResearchConceptsPharmacokinetic outcomesPK outcomesYounger age groupsDose-response studyBDCM concentrationsLarge inter-individual differencesPediatric populationLiver massBody weightAge groupsMicrosomal contentOral exposure routePharmacokinetic modelDose metricsDrink of waterEnzyme ontogenyOutcome variationEarly childhoodAdult findingsInter-individual differencesOutcomesNeonatesExposure routes
2008
Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition
Hines R, Koukouritaki S, Poch M, Stephens M. Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition. Drug Metabolism Reviews 2008, 40: 263-301. PMID: 18464046, DOI: 10.1080/03602530801952682.Peer-Reviewed Original ResearchConceptsRegulatory polymorphismsRegulatory sequencesHuman proteinsSelection pressureGene expressionCo-dominant traitEvolutionary perspectiveXenobiotic metabolismEnvironmental changesToxicant dispositionUnexpected paucityCurrent understandingHeterozygous stateTraitsPolymorphismSuch variationExpressionKnowledge gapsGenesProteinFitnessSequenceMetabolismVariationDrug disposition
2006
The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
Krueger S, VanDyke J, Williams D, Hines R. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines. Drug Metabolism Reviews 2006, 38: 139-147. PMID: 16684653, DOI: 10.1080/03602530600569919.Peer-Reviewed Original ResearchConceptsMetabolism of tamoxifenBreast cancer therapyHuman liver microsomesFlavin-Containing MonooxygenaseMetabolic activation pathwayEndometrial cancerTamoxifen metabolismN-oxide productionLiver microsomesTamoxifenMetabolic activationDNA adductionCancer therapyActivation pathwayCytochrome P450Detoxication pathwayN-oxygenationRiskMetabolismLow levelsPathwayChemopreventionNeoplasiaTherapyCancer
1993
Expression of human cytochrome P450 1A1 in DNA repair deficient and proficient human fibroblasts stably transformed with an inducible expression vector
States J, Quan T, Hines R, Novak R, Runge-Morris M. Expression of human cytochrome P450 1A1 in DNA repair deficient and proficient human fibroblasts stably transformed with an inducible expression vector. Carcinogenesis 1993, 14: 1643-1649. PMID: 8353849, DOI: 10.1093/carcin/14.8.1643.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideAnimalsBase SequenceBenzo(a)pyreneBenzoflavonesBiotransformationCadmiumCadmium CompoundsChimeraCytochrome P-450 Enzyme SystemDNA RepairEnzyme InductionFibroblastsGene Expression Regulation, EnzymologicGenetic VectorsHumansIsoenzymesMiceMolecular Sequence DataPlasmidsRNA, MessengerSulfatesTransfectionTransformation, GeneticXeroderma PigmentosumConceptsCytochrome P450 1A1P450 1A1Inducible CYP1A1Inducible mouse metallothionein-I promoterLow dosesHuman skin fibroblastsProficient cellsPotent mutagenic agentCYP1A1 expressionCYP1A1 activityHuman cytochrome P450 1A1DNA repairCYP1A1Mouse metallothionein-I promoterCytotoxic effectsMetallothionein-I promoterSkin fibroblastsDifferential cytotoxicityDNA repair-proficient cellsToxic effectsMore cytotoxicCytochrome P450Normal cellsRepairHuman CYP1A1
1982
Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line p815) cells
Wiebkin P, Sieg M, Nelson R, Hines R, Prough R. Inhibition of metabolism-mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma (line p815) cells. Biochemical Pharmacology 1982, 31: 2921-2928. PMID: 6814447, DOI: 10.1016/0006-2952(82)90264-7.Peer-Reviewed Original Research
1981
Inhibition of metabolism--mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma cells (line P815).
Wiebkin P, Hines R, Nelson R, Prough R. Inhibition of metabolism--mediated cytotoxicity by 1,1-disubstituted hydrazines in mouse mastocytoma cells (line P815). 1981, 136 Pt B: 1067-75. PMID: 7344500.Peer-Reviewed Original Research